Condition: Obesity and Obesity-related Medical Conditions · Obesity and Overweight · Obesity Prevention · Sponsor: Dr. Christopher McGowan
The purpose of this study is to assess the effect of gastric fundal mucosal ablation (GFMA) on weight trajectory following discontinuation of once-weekly semaglutide or tirzepatide in adults with obesity. In this study, GFMA will be performed on patients who have experienced \> 10% weight loss with GLP-1 therapy and who plan to discontinue use of GLP-1 medications for the duration of the study.
This description comes directly from the study's public registry record.
Shannon Casey, MS · (919) 391-7843 · Shannon@trueyouweightloss.com
Chase Wooley, BS · (984) 345-2988 · Chase@trueyouweightloss.com
Always discuss trial participation with your own doctor first.
| True You Weight Loss | Cary, North Carolina, United States | Not Yet Recruiting |
| True You Weight Loss | Cary, North Carolina, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06734312